| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.21 | 2e-05 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.17 | 0.0008 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.13 | 0.005 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.097 | 0.05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.089 | 0.06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.081 | 0.1 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.076 | 0.1 |